+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07607587

Safety and Tolerability of Cagrilintide Compared to Placebo in Adults with Obesity Who Discontinued GLP-1-RA Therapy Due to Gastrointestinal Side Effects

Led by Novo Nordisk A/S · Updated on 2026-10-19

114

Participants Needed

13

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety of the medicine Cagrilintide compared to a placebo in adults who do not tolerate marketed glucagon-like peptide-1 GLP-1 therapies and who live with overweight or obesity. The study focuses on people who have stopped GLP-1 receptor agonist treatments due to gastrointestinal side effects and aims to see how well participants tolerate Cagrilintide. Participants are randomly assigned to receive either Cagrilintide or a placebo that looks like Cagrilintide but has no active medicine. Both treatments are administered by injection under the skin and last for 26 weeks. The study is double-blinded, meaning neither participants nor researchers know who receives which treatment, and it is planned to last about 8 months in total. During the study, participants will be monitored to see if they can stay on the standard or higher dose of Cagrilintide or placebo at week 26. Researchers will collect health data and assess tolerability throughout the treatment period. The study is sponsored by Novo Nordisk AS and includes adults 18 years or older with a body mass index of 30 kgm or higher who have discontinued GLP-1-RA therapy due to gastrointestinal issues.

CONDITIONS

Brief Title

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

Research Team

N

Novo Nordisk

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here